{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T08:49:45Z","timestamp":1769244585526,"version":"3.49.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.semarthrit.2018.06.003","type":"journal-article","created":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T04:19:08Z","timestamp":1529641148000},"page":"597-602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center"],"prefix":"10.1016","volume":"48","author":[{"given":"Evripidis","family":"Kaltsonoudis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9383-5722","authenticated-orcid":false,"given":"Eleftherios","family":"Pelechas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paraskevi V.","family":"Voulgari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2232-0326","authenticated-orcid":false,"given":"Alexandros A.","family":"Drosos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2018.06.003_bib0001","first-page":"S20","article-title":"Epidemiology of rheumatoid arthritis","volume":"3","author":"Drosos","year":"2004","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.semarthrit.2018.06.003_bib0002","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.autrev.2004.09.002","article-title":"Epidemiology of adult rheumatoid arthritis","volume":"4","author":"Alamanos","year":"2005","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.semarthrit.2018.06.003_bib0003","first-page":"2129","article-title":"Epidemiology of adult rheumatoid arthritis in northwest Greece 1987\u20131995","volume":"24","author":"Drosos","year":"1997","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2018.06.003_bib0004","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.semarthrit.2006.08.006","article-title":"Incidence and prevalence of rheumatoid arthritis, based on the 1987 American college of rheumatology criteria: a systematic review","volume":"36","author":"Alamanos","year":"2006","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2018.06.003_bib0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2018.06.003_bib0006","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2018.06.003_bib0007","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1002\/art.21503","article-title":"Progress toward the cure of rheumatoid arthritis? The best study","volume":"52","author":"Weisman","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2018.06.003_bib0008","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/acr.21997","article-title":"Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States during 1983\u20132009","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"10.1016\/j.semarthrit.2018.06.003_bib0009","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1517\/14712598.2012.721771","article-title":"Adalimumab in the treatment of rheumatoid arthritis","volume":"12","author":"Voulgari","year":"2012","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.semarthrit.2018.06.003_bib0010","first-page":"415","article-title":"Certolizumab for rheumatoid arthritis","volume":"32","author":"Markatseli","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.06.003_bib0011","first-page":"570","article-title":"Golimumab, the newest TNF-\u03b1 blocker, comes of age","volume":"33","author":"Papagoras","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"17","key":"10.1016\/j.semarthrit.2018.06.003_bib0012","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","article-title":"A review in rheumatoid arthritis","volume":"77","author":"Tocilizumab","year":"2017","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.semarthrit.2018.06.003_bib0013","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1517\/14712598.2011.592825","article-title":"Abatacept: a biologic immune modulator for rheumatoid arthritis","volume":"11","author":"Papagoras","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.semarthrit.2018.06.003_bib0014","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.2147\/DDDT.S139248","article-title":"Current perspective on rituximab in rheumatic diseases","volume":"11","author":"Schioppo","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.06.003_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2018.06.003_bib0016","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"Update of EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2018.06.003_bib0017","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/art.24511","article-title":"Patient-reported outcomes following biologic therapy in a sample of adults with rheumatoid arthritis recruited from community-based rheumatologists","volume":"61","author":"Katz","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semarthrit.2018.06.003_bib0018","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/rheumatology\/keh237","article-title":"Patients\u2019 perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study","volume":"43","author":"Marshall","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.06.003_bib0019","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/rheumatology\/keh412","article-title":"Rheumatology outcomes: the patient's perspective. A multicenter focus group interview study of Swedish rheumatoid arthritis patients","volume":"44","author":"Ahlmen","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2018.06.003_bib0020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s13075-017-1445-3","article-title":"Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?","volume":"19","author":"Romao","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.semarthrit.2018.06.003_bib0021","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/acr.21662","article-title":"Disease activity and disability in women and men with early rheumatoid arthritis (RA): An 8-year followup of a Swedish early RA project","volume":"64","author":"Hallert","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2018.06.003_bib0022","doi-asserted-by":"crossref","first-page":"R42","DOI":"10.1186\/ar2951","article-title":"Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA Study","volume":"12","author":"Sokka","year":"2010","journal-title":"Arthritis Res Therapy"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.06.003_bib0023","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"Hetland","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.semarthrit.2018.06.003_bib0024","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1136\/ard.2008.098467","article-title":"Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide","volume":"68","author":"Strangfeld","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.06.003_bib0025","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1749-6632.2009.04621.x","article-title":"TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice","volume":"1173","author":"Marchesoni","year":"2009","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.semarthrit.2018.06.003_bib0026","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","article-title":"Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period","volume":"8","author":"Gomez-Reino","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.06.003_bib0027","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.semarthrit.2013.07.011","article-title":"Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the hellenic registry of biologics: low rates of remission and 5-year drug survival","volume":"43","author":"Flouri","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.06.003_bib0028","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4236\/ojra.2013.32011","article-title":"Unmet needs in the treatment of rheumatoid arthritis","volume":"3","author":"Pope","year":"2013","journal-title":"Open J Rheum Autoimmun Dis"},{"key":"10.1016\/j.semarthrit.2018.06.003_bib0029","article-title":"Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need","author":"de Hair","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2018.06.003_bib0030","article-title":"The unmet need in rheumatology: reports from the targeted therapies meeting 2017","volume":"12","author":"Winthrop","year":"2017","journal-title":"Clin Immunol"},{"issue":"9","key":"10.1016\/j.semarthrit.2018.06.003_bib0031","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.autrev.2017.07.012","volume":"16","author":"Giacomelli","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.semarthrit.2018.06.003_bib0032","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00296-015-3415-x","article-title":"A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective","volume":"36","author":"Taylor","year":"2016","journal-title":"Rheumatol Int"},{"issue":"11","key":"10.1016\/j.semarthrit.2018.06.003_bib0033","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/rheumatology\/35.11.1101","article-title":"Remission in a prospective study of patients with rheumatoid arthritis. American rheumatism association preliminary remission criteria in relation to the disease activity score","volume":"35","author":"Prevoo","year":"1996","journal-title":"Br J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2018.06.003_bib0034","first-page":"743","article-title":"How to read radiographs according to the Sharp\/van der Heijde method","volume":"26","author":"Van der Heijde","year":"1999","journal-title":"J Rheumatol"},{"issue":"Suppl 5","key":"10.1016\/j.semarthrit.2018.06.003_bib0035","doi-asserted-by":"crossref","first-page":"v48","DOI":"10.1093\/rheumatology\/kes122","article-title":"Developing an effective treatment algorithm for rheumatoid arthritis","volume":"51","author":"Keystone","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.semarthrit.2018.06.003_bib0036","doi-asserted-by":"crossref","first-page":"406","DOI":"10.7326\/0003-4819-146-6-200703200-00005","article-title":"Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial","volume":"146","author":"Goekoop-Ruiterman","year":"2007","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.semarthrit.2018.06.003_bib0037","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1136\/ard.2010.146662","article-title":"Treating rheumatoid arthritis to target: the patient version of the international recommendations","volume":"70","author":"De Wit","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"9430","key":"10.1016\/j.semarthrit.2018.06.003_bib0038","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomized controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.semarthrit.2018.06.003_bib0039","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/ard.2007.071092","article-title":"Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer assisted management in early rheumatoid arthritis (CAMERA, an open-label strategy trial)","volume":"66","author":"Verstappen","year":"2007","journal-title":"Rheum Dis"},{"issue":"5 Suppl 61","key":"10.1016\/j.semarthrit.2018.06.003_bib0040","first-page":"S3","article-title":"Methotrexate: from its introduction to non-oncologic therapeutics to anti-TNF-\u03b1","volume":"28","author":"Benedek","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.06.003_bib0041","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2217\/ijr.12.10","article-title":"Current and future role of methotrexate in the therapeutic armamentarium for rheumatoid arthritis","volume":"7","author":"Kaltsonoudis","year":"2012","journal-title":"Int J Clin Rheum"},{"issue":"12","key":"10.1016\/j.semarthrit.2018.06.003_bib0042","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2016.175","article-title":"Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers","volume":"12","author":"Brown","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 3","key":"10.1016\/j.semarthrit.2018.06.003_bib0043","article-title":"Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility","volume":"66","author":"Bakker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.06.003_bib0044","first-page":"261","article-title":"Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study","volume":"29","author":"Papadopoulos","year":"2002","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2018.06.003_bib0045","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","article-title":"Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"9688","key":"10.1016\/j.semarthrit.2018.06.003_bib0046","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(09)60944-2","article-title":"Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial","volume":"374","author":"van Vollenhoven","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.06.003_bib0047","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1303006","article-title":"Therapies for active rheumatoid arthritis after methotrexate failure","volume":"369","author":"O'Dell","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.semarthrit.2018.06.003_bib0048","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/art.34498","article-title":"A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial","volume":"64","author":"Moreland","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.06.003_bib0049","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1056\/NEJMe1306381","article-title":"Making rational treatment decisions in rheumatoid arthritis when methotrexate fails","volume":"369","author":"Bathon","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2018.06.003_bib0050","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.amjmed.2005.01.029","article-title":"Infliximab therapy in established rheumatoid arthritis: an observational study","volume":"118","author":"Voulgari","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2018.06.003_bib0051","first-page":"31","article-title":"Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study","volume":"30","author":"Markatseli","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2018.06.003_bib0052","first-page":"625","article-title":"Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial","volume":"34","author":"Kremer","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2018.06.003_bib0053","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000515","article-title":"Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the \u201cORA\u201d registry","volume":"3","author":"Nourisson","year":"2017","journal-title":"RMD Open"},{"issue":"9","key":"10.1016\/j.semarthrit.2018.06.003_bib0054","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s10067-017-3742-2","article-title":"Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US corrona registry","volume":"36","author":"Salomon","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2018.06.003_bib0055","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2013-203993","article-title":"Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2018.06.003_bib0056","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.2016.13512","article-title":"Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial","volume":"316","author":"Gottenberg","year":"2016","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.semarthrit.2018.06.003_bib0057","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinic al trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2018.06.003_bib0058","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","article-title":"Safety and efficacy of baricitinib at 24\u2005weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate","volume":"74","author":"Keystone","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2018.06.003_bib0059","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/11531980-000000000-00000","article-title":"Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity","volume":"70","author":"Strand","year":"2010","journal-title":"Drugs"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218301884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218301884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T17:10:48Z","timestamp":1720372248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017218301884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0049017218301884"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.06.003","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}